330 related articles for article (PubMed ID: 24524212)
1. Lack of congruence between patients' and health professionals' perspectives of adherence to imatinib therapy in treatment of chronic myeloid leukemia: A qualitative study.
Wu S; Chee D; Ugalde A; Butow P; Seymour J; Schofield P
Palliat Support Care; 2015 Apr; 13(2):255-63. PubMed ID: 24524212
[TBL] [Abstract][Full Text] [Related]
2. Exploring chronic myeloid leukemia patients' reasons for not adhering to the oral anticancer drug imatinib as prescribed.
Eliasson L; Clifford S; Barber N; Marin D
Leuk Res; 2011 May; 35(5):626-30. PubMed ID: 21095002
[TBL] [Abstract][Full Text] [Related]
3. Disease acceptance and adherence to imatinib in Taiwanese chronic myeloid leukaemia outpatients.
Chen LC; Chen TC; Huang YB; Chang CS
Int J Clin Pharm; 2014 Feb; 36(1):120-7. PubMed ID: 24154825
[TBL] [Abstract][Full Text] [Related]
4. Comprehensive Evaluation of Adherence to Therapy, Its Associations, and Its Implications in Patients With Chronic Myeloid Leukemia Receiving Imatinib.
Unnikrishnan R; Veeraiah S; Mani S; Rajendranath R; Rajaraman S; Vidhubala Elangovan GS; Radhakrishnan V; Ganesan TS; Sagar TG; Ganesan P
Clin Lymphoma Myeloma Leuk; 2016 Jun; 16(6):366-371.e3. PubMed ID: 27052853
[TBL] [Abstract][Full Text] [Related]
5. Impact of oncology pharmacist-managed oral anticancer therapy in patients with chronic myelogenous leukemia.
Lam MS; Cheung N
J Oncol Pharm Pract; 2016 Dec; 22(6):741-748. PubMed ID: 26419691
[TBL] [Abstract][Full Text] [Related]
6. Cost sharing and adherence to tyrosine kinase inhibitors for patients with chronic myeloid leukemia.
Dusetzina SB; Winn AN; Abel GA; Huskamp HA; Keating NL
J Clin Oncol; 2014 Feb; 32(4):306-11. PubMed ID: 24366936
[TBL] [Abstract][Full Text] [Related]
7. Imatinib-induced thyroiditis in Philadelphia chromosome-positive chronic myeloid leukemia.
Singh S; Sharma PK
Indian J Pharmacol; 2016; 48(4):458-459. PubMed ID: 27756963
[TBL] [Abstract][Full Text] [Related]
8. Preliminary validation of self-assessment tool to measure imatinib adherence in patients with chronic myeloid leukemia.
Daouphars M; Ouvry M; Lenain P; Rouvet J; Jardin F; Bubenheim M; Varin R
Pharmacotherapy; 2013 Feb; 33(2):152-6. PubMed ID: 23359430
[TBL] [Abstract][Full Text] [Related]
9. Adherence to imatinib among patients attending Saskatchewan Cancer Agency Pharmacies.
Dicus M; Lyons B; Olson C; Tran DA; Blackburn DF
J Oncol Pharm Pract; 2015 Dec; 21(6):403-8. PubMed ID: 24903271
[TBL] [Abstract][Full Text] [Related]
10. No margin for non-adherence: Probabilistic kaplan-meier modeling of imatinib non-adherence and treatment response in CML (ADAGIO study).
Obeng-Kusi M; MacDonald K; van Lierde MA; Lee CS; De Geest S; Abraham I
Leuk Res; 2021 Dec; 111():106734. PubMed ID: 34735932
[TBL] [Abstract][Full Text] [Related]
11. Profiling chronic myeloid leukemia patients reporting intentional and unintentional non-adherence to lifelong therapy with tyrosine kinase inhibitors.
Efficace F; Rosti G; Cottone F; Breccia M; Castagnetti F; Iurlo A; Mandelli F; Baccarani M
Leuk Res; 2014 Mar; 38(3):294-8. PubMed ID: 23906625
[TBL] [Abstract][Full Text] [Related]
12. Intentional and unintentional treatment nonadherence in patients with systemic lupus erythematosus.
Daleboudt GM; Broadbent E; McQueen F; Kaptein AA
Arthritis Care Res (Hoboken); 2011 Mar; 63(3):342-50. PubMed ID: 21120967
[TBL] [Abstract][Full Text] [Related]
13. Medication adherence perspectives in haemodialysis patients: a qualitative study.
Ghimire S; Castelino RL; Jose MD; Zaidi STR
BMC Nephrol; 2017 May; 18(1):167. PubMed ID: 28532480
[TBL] [Abstract][Full Text] [Related]
14. Prevalence and determinants of non-adherence to Imatinib in the first 3-months treatment among newly diagnosed Ethiopian's with chronic myeloid leukemia.
Mulu Fentie A; Tadesse F; Engidawork E; Gebremedhin A
PLoS One; 2019; 14(3):e0213557. PubMed ID: 30845227
[TBL] [Abstract][Full Text] [Related]
15. Imatinib mesylate induced erythroderma: A rare case series.
Kumar S; Mahajan BB; Kaur S; Banipal RP; Singh A
J Cancer Res Ther; 2015; 11(4):993-6. PubMed ID: 26881566
[TBL] [Abstract][Full Text] [Related]
16. Adherence to multiple, prescribed medications in diabetic kidney disease: A qualitative study of consumers' and health professionals' perspectives.
Williams AF; Manias E; Walker R
Int J Nurs Stud; 2008 Dec; 45(12):1742-56. PubMed ID: 18701103
[TBL] [Abstract][Full Text] [Related]
17. Long-term treatment with imatinib results in profound mast cell deficiency in Ph+ chronic myeloid leukemia.
Cerny-Reiterer S; Rabenhorst A; Stefanzl G; Herndlhofer S; Hoermann G; Müllauer L; Baumgartner S; Beham-Schmid C; Sperr WR; Mannhalter C; Sill H; Linkesch W; Arock M; Hartmann K; Valent P
Oncotarget; 2015 Feb; 6(5):3071-84. PubMed ID: 25605011
[TBL] [Abstract][Full Text] [Related]
18. Phase IV study evaluating efficacy of escalated dose of imatinib in chronic myeloid leukemia patients showing suboptimal response to standard dose imatinib.
Koh Y; Kim I; Yoon SS; Kim BK; Kim DY; Lee JH; Lee KH; Park E; Kim HJ; Sohn SK; Joo YD; Kim SJ; Chung J; Shin HJ; Kim SH; Kim CS; Song HS; Kim MK; Hyun MS; Ahn JS; Jung CW; Park S;
Ann Hematol; 2010 Jul; 89(7):725-31. PubMed ID: 20179930
[TBL] [Abstract][Full Text] [Related]
19. Continuing Imatinib Treatment for Chronic Myeloid Leukemia Patients Who Had Serious Adverse Events at the Onset of Therapy.
Li Y; Wang CL; Din B; Yu L; Zhu J
Acta Haematol; 2017; 137(3):158-162. PubMed ID: 28399540
[No Abstract] [Full Text] [Related]
20. Intentional Nonadherence as a Means to Exert Control.
Huyard C; Derijks L; Haak H; Lieverse L
Qual Health Res; 2017 Jul; 27(8):1215-1224. PubMed ID: 28682739
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
